Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti-CTLA-4 treatment prolongs overall survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells. METHODS: We obtained tumor tissue from patients with melanoma who were treated with ipilimumab or tremelimumab. Whole-exome sequencing was performed on tumors and matched blood samples. Somatic mutations and candidate neoantigens generated from these mutations were characterized. Neoantigen peptides were tested for the ability to activate lymphocytes from ipilimumab-treated patients. RESULTS: Malignant melanoma exomes from 64 patients treated with CTLA-4 blockade were characterized with the use of massively parallel sequencing. A discovery set consisted of 11 patients who derived a long-term clinical benefit and 14 patients who derived a minimal benefit or no benefit. Mutational load was associated with the degree of clinical benefit (P=0.01) but alone was not sufficient to predict benefit. Using genomewide somatic neoepitope analysis and patient-specific HLA typing, we identified candidate tumor neoantigens for each patient. We elucidated a neoantigen landscape that is specifically present in tumors with a strong response to CTLA-4 blockade. We validated this signature in a second set of 39 patients with melanoma who were treated with anti-CTLA-4 antibodies. Predicted neoantigens activated T cells from the patients treated with ipilimumab. CONCLUSIONS: These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA-4 agents are being considered. (Funded by the Frederick Adler Fund and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“external validation using the Snyder cohort substantiated the model’s robust performance characteristics, maintaining exceptional predictive capability for immunotherapeutic response assessment (AUC = 0.769, AUPRC = 0.722, Fisher’s exact test P = 2.42 × 10−5; Fig. 4, A to C).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [38]
In the citing paper
“As both classes of HLA molecule have previously been shown to have a central role in CD8+ and CD4+ T cell immunity43–49”
From Identification of bacteria-derived HLA-bound peptides in melanoma (2021) · cites this paper as [47]
In the citing paper
“Indeed, as mentioned in the previous section, both PD-1 and CTLA-4 blockades are more effective in tumors that are infiltrated by T cells or that have high mutation rates and are therefore more immunogenic prior to treatment (86–88).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [87]
In the citing paper
“This was particularly noted in anti-CTLA-4-treated melanoma patients whose tumors displayed neo-antigens (87) and similarly in anti-PD-1-treated patients with colorectal cancers or non-small cell lung cancers that were mismatch-repair deficient or had high mutation rates, respectively (78, 86).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [87]
In the citing paper
“In keeping with a more complex genomic landscape and a larger burden of clonal or sub-clonal co-drivers, multiple clinical studies have identified TP53 co-alterations as a negative prognostic marker in EGFR-mutant LUAD and a consistent predictor of worse clinical outcomes following EGFR TKI therapy72, 73, 111–116.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [111]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Above normal 2 (18) 5 (36) 3 (12) 3 (21)”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288 · cited 1×
“Not available 1 (9) 1 (7) 14 (56) 2 (14)”
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810 · cited 1×
“Not available 1 (9) 1 (7) 14 (56) 2 (14)”
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
An immune-active tumor microenvironment favors clinical response to ipilimumab
Ji, R.-R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N. O., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 775
Self-citationMelanoma genome sequencing reveals frequent PREX2 mutations
Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., Ivanova, E., Watson, I. R., Nickerson, E., Ghosh, P., et al. (2012) · Nature · doi:10.1038/nature11071 · Cited by 756 · cited 1×
“Above normal 2 (18) 5 (36) 3 (12) 3 (21)”
Deconstructing the Peptide-MHC Specificity of T Cell Recognition
Birnbaum, M. E., Mendoza, J. L., Sethi, D. K., Dong, S., Glanville, J., Dobbins, J., Özkan, E., Davis, M. M., Wucherpfennig, K. W., & Garcia, K. C. (2014) · Cell · doi:10.1016/j.cell.2014.03.047 · Cited by 556 · cited 1×
“Above normal 2 (18) 5 (36) 3 (12) 3 (21)”
Exome sequencing identifies GRIN2A as frequently mutated in melanoma
Program, N. C. S., Wei, X., Walia, V., Lin, J. C., Teer, J. K., Prickett, T. D., Gartner, J., Davis, S., Stemke-Hale, K., Davies, M. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.810 · Cited by 471
Ku, G. Y., Yuan, J., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010) · Cancer · doi:10.1002/cncr.24951 · Cited by 422
Self-citationEpitope Landscape in Breast and Colorectal Cancer
Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383
Self-citationAnti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 378 · cited 1×
“Not available 1 (9) 1 (7) 14 (56) 2 (14)”
Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope
Allen, P. M., Matsueda, G. R., Evans, R. J., Dunbar, Jr., Marshall, G. R., & Unanue, E. R. (1987) · Nature · doi:10.1038/327713a0 · Cited by 291
Gajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250
Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide MHC Confinement Time
Aleksic, M., Dushek, O., Zhang, H., Shenderov, E., Chen, J.-L., Cerundolo, V., Coombs, D., & van der Merwe, P. A. (2010) · Immunity · doi:10.1016/j.immuni.2009.11.013 · Cited by 249
A unique tumor antigen produced by a single amino acid substitution
Monach, P. A., Meredith, S. C., T.Siegel, C., & Schreiber, H. (1995) · Immunity · doi:10.1016/1074-7613(95)90078-0 · Cited by 241
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
Noguchi, Y., Chen, Y. T., & Old, L. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3171 · Cited by 173
Dubey, P., Hendrickson, R. C., Meredith, S. C., Siegel, C., Shabanowitz, J., Skipper, J., Engelhard, V. H., Hunt, D. F., & Schreiber, H. W. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.4.695 · Cited by 161
Wolchok, J. D., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Schadendorf, D., de Pril, V., Heller, K. N., Chen, T., Ibrahim, R. A., et al. (2010) · PubMed · Cited by 151
Self-citationStuart, G. W., Moffett, K., & Leader, J. J. (2002) · Molecular Biology and Evolution · doi:10.1093/oxfordjournals.molbev.a004111 · Cited by 111
Piotr Sliz, A., Michielin, O. A., Cerottini, J., Luescher, I. F., Romero, P. J., Karplus, M., & Wiley, D. C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.6.3276 · Cited by 86
Insaidoo, F. K., Borbulevych, O. Y., Hossain, M., Santhanagopolan, S. M., Baxter, T. K., & Baker, B. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.283564 · Cited by 55
Li, Y., Depontieu, F., Sidney, J., Salay, T. M., Engelhard, V. H., Hunt, D. F., Sette, A., Topalian, S. L., & Mariuzza, R. A. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.04.037 · Cited by 50
Self-citationWong, R. M. H., Lau, R., Chang, J. R., Kuus-Reichel, T., Brichard, V. G., Bruck, C., & Weber, J. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0241 · Cited by 49
Development and Validation of a Prognostic Gene-Expression Signature for Lung Adenocarcinoma
Park, Y.-Y., Park, E. S., Kim, S. B., Kim, S. C., Sohn, B. H., Chu, I., Jeong, W., Mills, G. B., Byers, L. A., & Lee, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044225 · Cited by 42
Modeling the Repertoire of True Tumor-Specific MHC I Epitopes in a Human Tumor
Srivastava, N., & Srivastava, P. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006094 · Cited by 29
Srivastava, P. K., & Duan, F. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1422-x · Cited by 25 · cited 1×
“Above normal 2 (18) 5 (36) 3 (12) 3 (21)”
Cutting Edge: TCR Contacts as Anchors: Effects on Affinity and HLA-DM Stability
Anderson, M. W., & Gorski, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5683 · Cited by 21
Lim, J., Kim, H. O., Jeong, S. H., Ha, J. E., Jang, S., Lee, S., Lee, K., & Stroncek, D. F. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-72 · Cited by 20
Morita, D., Yamamoto, Y., Suzuki, J., Mori, N., Igarashi, T., & Sugita, M. (2012) · Journal of Virology · doi:10.1128/jvi.02142-12 · Cited by 14
Immune response to synthetic peptides of hepatitis delta antigen
Poisson, F., Baillou, F., Dubois, F., Janvier, B., Roingeard, P., & Goudeau, A. (1993) · Journal of Clinical Microbiology · doi:10.1128/jcm.31.9.2343-2349.1993 · Cited by 13
Research works printed but not linked: 1
- Wolchok JD, 2010, Cancer Immun, 10, 9
Cited by
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
“They support the view that the number and type of alterations may prove to be valuable for judging the potential usefulness of immune checkpoint inhibitors, even in mismatch repair–proficient cancers.(41,48,54) Most importantly, our results show an approach for the treatment of a specific class of tumors that is based…”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationCancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“Overcoming Resistance to Immunotherapy On the basis of insights gained (Hugo et al., 2016; Snyder et al., 2014; Van Allen et al., 2015), efforts are currently underway to derive actionable strategies to combat therapeutic resistance to immunotherapy.”
InfluentialSelf-citation
Metadata
- Authors
- Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., Hollmann, T. J., Bruggeman, C., Kannan, K., Li, Y., Elipenahli, C., Liu, C., Harbison, C. T., Wang, L., Ribas, A., Wolchok, J. D., & Chan, T. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2189-2199
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4315319
- OpenAlex
- W2104885590
- Cited by
- 4,286
- References
- 37
- Citations by year
- 2026: 100 · 2025: 190 · 2024: 249 · 2023: 291 · 2022: 410 · 2021: 436 · 2020: 460 · 2019: 434 · 2018: 464 · 2017: 479 · 2016: 436 · 2015: 316 · 2014: 11
- FWCI
- 200.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (T32CA009512, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- melanoma, CTLA-4 blockade, ipilimumab, tremelimumab, immune checkpoint inhibitors, neoantigens, somatic mutations, mutational load, predictive biomarkers, T cell activation, HLA typing, exome sequencing, clinical response prediction
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Histocompatibility Testing, Humans, Male, Melanoma, Middle Aged, Mutation, Skin Neoplasms, High-Throughput Nucleotide Sequencing, Exome, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.